NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Hall Caroline J.; Doss Sally; Hay Nicola; Sutcliffe Frances; Stevens Andrew

首页> 外文期刊>The lancet oncology >NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

【24h】

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

机译：NICE关于Panobinostat治疗多发性骨髓瘤患者的指南，至少经过两次先前的治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2016年第3期|共2页
作者
Hall Caroline J.; Doss Sally; Hay Nicola; Sutcliffe Frances; Stevens Andrew;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments [J] . Hall Caroline J., Doss Sally, Hay Nicola, The lancet oncology . 2016,第3期

机译：NICE关于Panobinostat治疗多发性骨髓瘤患者的指南，至少经过两次先前的治疗
2. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data [J] . Istvan Majer, Gijs van de Wetering, Zoltan Polanyi, Applied health economics and health policy . 2017,第1期

机译：Panobinostat Plus Bortezomib与近年三体醛患者在复发和/或难治性多发性骨髓瘤中：使用患者级数据的匹配调整的间接治疗比较生存结果的比较
3. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat ( MUK MUK six open label, multi‐centre phase I/ II II Clinical Trial) [J] . Popat Rakesh, Brown Sarah R., Flanagan Louise, British Journal of Haematology . 2019,第3期

机译：延长后续随访和Panobinostat对复发多发性骨髓瘤患者的患者的可行性，用Bortezomib，沙利度胺，Dexamethasone加上Panobinostat（Muk Muk六个开放标签，多中心I / II II II II临床试验）
4. Analysis of the secondary structure of blood serum proteins from patients with multiple myeloma [C] . M O Kobeleva, E A Telnaya, L V Plotnikova, International Conference PhysicA.SPb . 2020

机译：多发性骨髓瘤患者血清血清蛋白二次结构分析
5. Heparanase drives the aggressive myeloma phenotype: Preclinical development of a heparanase inhibitor for the treatment of multiple myeloma. [D] . Ritchie, Joseph P. 2010

机译：乙酰肝素酶驱动侵袭性骨髓瘤表型：用于治疗多发性骨髓瘤的乙酰肝素酶抑制剂的临床前开发。
6. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma [O] . Kyriaki Tzogani, Paula Van Hennik, Ita Walsh, 2018

机译：Panobinostat（Farydak）的EMA综述治疗成年复发和/或难治性多发性骨髓瘤患者
7. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma [O] . Kyriaki Tzogani, Paula Van Hennik, Ita Walsh, 2018

机译：Panobinostat（Farydak）的EMA综述用于治疗成人复发和/或难治性多发性骨髓瘤的患者

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

著录项

相似文献

相关主题

期刊订阅